ScoreHaematology

MGUS risk of progression (Mayo)

Stratifies the 20-year risk of progression of monoclonal gammopathy of undetermined significance using three factors.

Updated 30 October 2026

When to use it

Patients with newly diagnosed MGUS, to decide follow-up intensity and the need for bone marrow assessment.

What it needs

  • Serum M proteinUnits: g/L, g/dL
  • Heavy-chain isotypeOptions: IgG · Non-IgG (IgA, IgM, IgD or biclonal)
  • Free light chain kappa/lambda ratioUnits: κ/λ

The points for each answer and the automatic total are in the app.

How to interpret it

Risk factors
ResultInterpretation
≤ 0Low risk: ≈ 5 % progression at 20 years
1Low-intermediate risk: ≈ 21 % at 20 years
2High-intermediate risk: ≈ 37 % at 20 years
≥ 3High risk: ≈ 58 % at 20 years

Practical tip

Low-risk MGUS (no factors) can be followed with a review at 6 months and then every 2–3 years unless symptoms appear.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top